Physician profile
Patrick L Stieve
NPI 1770863565
$4,359.25
in general payments reported to CMS, 2019-2025
22 companies · $990 in 2025
The $990 reported for 2025 was more than what 87% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $521 · 2022: $595 · 2023: $1,115 · 2024: $1,138 · 2025: $990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,243.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,197.59 | 2021-2025 | Impella |
| Astrazeneca Pharmaceuticals LP | $403.64 | 2021-2023 | Breztri |
| Abbott Laboratories | $395.63 | 2024-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Abbvie INC. | $371.87 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $272.67 | 2024-2025 | Austedo Xr |
| Sanofi-Aventis U.S. LLC | $214.86 | 2023-2024 | |
| Inari Medical, INC. | $188.60 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Evoke Pharma, INC. | $125.00 | 2025 | |
| Amgen INC. | $121.82 | 2024 | Repatha |
| Novo Nordisk INC | $120.05 | 2021 | |
| Mylan Specialty L.P. | $120.02 | 2024 | Yupelri |
| Horizon Therapeutics Plc | $120.01 | 2023 | Uplizna |
| Idorsia Pharmaceuticals US INC | $114.91 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $113.68 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $110.56 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $101.68 | 2023 | Korlym |
| Heartflow, INC. | $101.06 | 2024 | |
| Novartis Pharmaceuticals Corporation | $68.85 | 2021-2022 | |
| Edwards Lifesciences Corporation | $31.35 | 2022 | |
| Boston Scientific Corporation | $30.11 | 2025 | Farapulse |
| Merck Sharp & Dohme LLC | $17.90 | 2021 | |
| Angiodynamics, INC. | $17.39 | 2025 | Alphavac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Stieve listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.